Neuroprotection by Lowering Cholesterol

  • Tatiana Borisova
Part of the SpringerBriefs in Neuroscience book series (BRIEFSNEUROSCI, volume 12)


In stroke, cerebral hypoxia/ischemia, and traumatic brain injury, the development of neurotoxocity is provoked by enhanced extracellular glutamate, which is released from nerve cells mainly by glutamate transporter reversal—a distinctive feature of these pathological states. Transporter-mediated glutamate release from the synaptosomes: (1) stimulated by depolarization of the plasma membrane; (2) by means of heteroexchange with competitive transportable inhibitor of glutamate transporters DL-threo-β-hydroxyaspartate; (3) in low-[Na+] medium; and (4) during dissipation of the proton gradient of synaptic vesicles by the protonophore FCCP; was decreased under conditions of cholesterol deficiency by approximately 24, 28, 40, 17%, respectively.

A decrease in the level of membrane cholesterol attenuated transporter-mediated glutamate release from nerve terminals. Therefore, lowering cholesterol may be used in neuroprotection in stroke, ischemia, and traumatic brain injury that are associated with an increase in glutamate uptake reversal. This data can explain the neuroprotective effects of statins in these pathological states and provide one of the mechanisms of their neuroprotective action. However, besides these disorders lowering cholesterol may cause harmful consequences decreasing glutamate uptake by nerve terminals.


Traumatic Brain Injury Synaptic Vesicle Nerve Terminal Glutamate Release Glutamate Transporter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abulrob A, Tauskela JS, Mealing G, Brunette E, Faid K, Stanimirovic D (2005) Protection by cholesterol-extracting cyclodextrins: a role for N-methyl-D-aspartate receptor redistribution. J Neurochem 92:1477–1486PubMedCrossRefGoogle Scholar
  2. Berger C, Xia F, Maurer MH, Schwab S (2008) Neuroprotection by pravastatin in acute ischemic stroke in rats. Brain Res Rev 58:48–56PubMedCrossRefGoogle Scholar
  3. Borisova T, Krisanova N, Sivko R, Borysov A (2010a) Cholesterol depletion attenuates tonic release but increases the ambient level of glutamate in rat brain synaptosomes. Neurochem Int 56:466–478PubMedCrossRefGoogle Scholar
  4. Borisova T, Sivko R, Borysov A, Krisanova N (2010b) Diverse presynaptic mechanisms underlying methyl-beta-cyclodextrin—mediated changes in glutamate transport. Cell Mol Neurobiol 30:1013–1023PubMedCrossRefGoogle Scholar
  5. Borisova T, Kasatkina L, Ostapchenko L (2011) The proton gradient of secretory granules and glutamate transport in blood platelets during cholesterol depletion of the plasma membrane by methyl-beta-cyclodextrin. Neurochem Int 59:965–975PubMedCrossRefGoogle Scholar
  6. Bösel J, Gandor F, Harms C et al (2005) Neuroprotective effects of atorvastatin against glutamate-­induced excitotoxicity in primary cortical neurones. J Neurochem 92:1386–1398PubMedCrossRefGoogle Scholar
  7. Butchbach M, Tian G, Guo H, Lin CL (2004) Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains. J Biol Chem 279:34388–34396PubMedCrossRefGoogle Scholar
  8. Camargo F, Erickson RP, Garver WS et al (2001) Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci 70:131–142PubMedCrossRefGoogle Scholar
  9. Chen J, Zhang C, Jiang H et al (2005) Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab 25:281–290PubMedCrossRefPubMedCentralGoogle Scholar
  10. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95:8880–8885PubMedCrossRefPubMedCentralGoogle Scholar
  11. Funck VR, Oliveira CV, Pereira LM et al (2011) Differential effects of atorvastatin treatment and withdrawal on pentylenetetrazol-induced seizures. Epilepsia 52:2094–2104PubMedCrossRefGoogle Scholar
  12. Hess DC, Demchuk AM, Brass LM, Yatsu FM (2000) HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology 54:790–796PubMedCrossRefGoogle Scholar
  13. Jabaudon D, Scanziani M, Gähwiler BH, Gerber U (2000) Acute decrease in net glutamate uptake during energy deprivation. Proc Natl Acad Sci USA 97:5610–5615PubMedCrossRefPubMedCentralGoogle Scholar
  14. Jennings LJ, Xu QW, Firth TA (1999) Cholesterol inhibits spontaneous action potentials and ­calcium currents in guinea pig gallbladder smooth muscle. Am J Physiol 277:1017–1026Google Scholar
  15. Kirsch C, Eckert GP, Mueller WE (2003) Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 65:843–856PubMedCrossRefGoogle Scholar
  16. Krisanova N, Sivko R, Kasatkina L, Borisova T (2012) Neuroprotection by lowering cholesterol: a decrease in membrane cholesterol content reduces transporter-mediated glutamate release from brain nerve terminals. Biochim Biophys Acta 1822:1013–1023Google Scholar
  17. Lang T, Bruns D, Wenzel D, Riedel D, Holroyd P, Thiele C, Jahn R (2001) SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. EMBO J 20:2202–2213PubMedCrossRefPubMedCentralGoogle Scholar
  18. Monnaert V, Tilloy S, Bricout H, Fenart L, Cecchelli R, Monflier E (2004) Behavior of alpha-, beta-, and gamma-cyclodextrins and their derivatives on an in vitro model of blood–brain barrier. J Pharmacol Exp Ther 310:745–751PubMedCrossRefGoogle Scholar
  19. Nagaraja TN, Knight RA, Croxen RL, Konda KP, Fenstermacher JD (2006) Acute neurovascular unit protection by simvastatin in transient cerebral ischemia. Neurol Res 28:826–830PubMedCrossRefGoogle Scholar
  20. O’Kane RL, Martínez-López I, DeJoseph MR, Viña JR, Hawkins RA (1999) Na+-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood–brain barrier. A mechanism for glutamate removal. J Biol Chem 274:31891–31895PubMedCrossRefGoogle Scholar
  21. Ponce J, de la Ossa NP, Hurtado O, Millan M, Arenillas JF, Dávalos A, Gasull T (2008) Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. Stroke 39:1269–1275PubMedCrossRefGoogle Scholar
  22. Ramirez C, Tercero I, Pineda A, Burgos JS (2011) Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment. J Alzheimers Dis 24:161–174PubMedGoogle Scholar
  23. Robinson MB (2006) Acute regulation of sodium-dependent glutamate transporters: a focus on constitutive and regulated trafficking. Handb Exp Pharmacol 175:251–275PubMedCrossRefGoogle Scholar
  24. Sierra S, Ramos MC, Molina P, Esteo C, Vázquez JA, Burgos JS (2011) Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood–brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 23:307–318PubMedGoogle Scholar
  25. Sironi L, Cimino M, Guerrini U et al (2003) Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 23:322–327PubMedCrossRefGoogle Scholar
  26. Sugiura S, Yagita Y, Sasaki T, Todo K, Terasaki Y, Ohyama N, Hori M, Kitagawa K (2007) Postischemic administration of HMG CoA reductase inhibitor inhibits infarct expansion after transient middle cerebral artery occlusion. Brain Res 1181:125–129PubMedCrossRefGoogle Scholar
  27. Wang Q, Zengin A, Deng C et al (2009) High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: the association with the up-regulation of NMDA receptor binding in the rat brain. Exp Neurol 216:132–138PubMedCrossRefGoogle Scholar
  28. Xu Y, Yan J, Zhou P, Li J, Gao H, Xia Y, Wang Q (2012) Neurotransmitter receptors and cognitive dysfunction in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol 97:1–13PubMedCrossRefPubMedCentralGoogle Scholar
  29. Yan J, Xu Y, Zhu C et al (2011) Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses. PLoS One 6:e20945PubMedCrossRefPubMedCentralGoogle Scholar
  30. Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S, Piser T (2003) 3-hydroxy-3-­methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 23:11104–11111PubMedGoogle Scholar
  31. Zhang L, Zhang ZG, Ding GL et al (2005) Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 112:3486–3494PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Tatiana Borisova
    • 1
  1. 1.Department of Neurochemistry Palladin Institute of BiochemistryNational Academy of Sciences of UkraineKievUkraine

Personalised recommendations